A Phase 3 interventional study of Filgotinib in Ulcerative Colitis, sponsored by Alfasigma S.p.A.. Recruiting at 46 sites in 13 countries. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Alfasigma S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Colitis, Ulcerative with a site in Italy — 48 open to participants now, 77 under way, 27 of them phase 3. Colitis, Ulcerative · Italy.
Among the 209 studies in Colitis, Ulcerative with a site in Italy, this one is the 130th largest by planned enrollment of the 175 interventional ones that give a count, is one of 19 that started in 2025, is one of 65 in phase 3, reaches primary completion later than 61 of the 76 other live ones, and was the 175th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →48 of the 209 studies in Colitis, Ulcerative with a site in Italy are open now. Recruiting first, the newest first:
Palisade Bio · Sites in Italy, United States, Canada and 9 more countries
Ages 18–75
Pfizer · Sites in Italy, United States, Australia and 7 more countries
Ages 2–11
Janssen Research & Development, LLC · Sites in Italy, United States, Argentina and 30 more countries
Ages 18+
Eli Lilly and Company · Sites in Italy, United States, Belgium and 7 more countries
Ages 18–80
University of Padova · Sites in Italy
Ages 18–75
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 8 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 77 · Phase 3 73 · Phase 4 9
First in 2003; this study’s year is marked. 19 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 182 across the 175 interventional studies, 279 across the 34 observational. Of the 122 that completed or were terminated, 74 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
153 of 209 have an industry lead sponsor. The 10 most frequent:
Alfasigma S.p.A. is the lead sponsor of 24 studies on the registry; 3 are open to participants now.
Alfasigma S.p.A. has 3 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
23 of the studies in Colitis, Ulcerative with a site in Italy that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 23 to your calendar (.ics) → With an account.
Among the 209 studies in Colitis, Ulcerative with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of filgotinib as a treatment for UC in children and adolescents aged from 8 to less than 18 years.
Approximately 80 subjects from 8 to \<18 years of age with moderately to severely active UC, including a minimum of 8 subjects from 8 to \<12 years of age, will be enrolled in this study.
During the study, eligible subjects will take the investigational product (IP) on-site at Week 4, Week 10, and Week 22 (in the morning; with or without food). On all other days, subjects will take IP at home (in the morning; with or without food).
Subjects who do not achieve mMCS remission and/or MCS response at Week 10 will continue with induction treatment until Week 22. Subjects who do not achieve PUCAI remission at Week 22 will be permanently discontinued from the study.
Subjects will all receive a filgotinib dose targeting the same systemic exposure as that observed in adults with UC treated with 200 mg q.d.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Filgotinib
Drug: Filgotinib
IP will be provided as commercially developed film-coated tablets (100 and 200 mg strength) or reduced-strength (65 mg) age-appropriate film-coated tablets for use in pediatric subjects aged at least 8 years and needs to be taken orally q.d. at approximately the same time every morning (with or without food).
Efficacy of filgotinib in induction of remission and maintenance of effect in pediatric subjects with ulcerative colitis (UC)
Proportion of subjects achieving clinical remission based on modified Mayo Clinical Score (mMCS)
Time frame: Week 10
subjects with ulcerative colitis (UC)
Proportion of subjects achieving clinical remission based on mMCS
Time frame: Week 58
Safety and tolerability of filgotinib in pediatric subjects with UC
Incidence of treatment-emergent adverse events (TEAEs), adverse events of interest, and laboratory abnormalities through follow-up
Time frame: Week 62
Safety and tolerability of filgotinib in pediatric subjects with UC
Change from baseline in body mass index (BMI)
Time frame: Week 58
Safety and tolerability of filgotinib in pediatric subjects with U
Change from baseline in height velocity
Time frame: Week 58
Started Sep 2025 (actual). Primary completion is estimated for Jun 2028, 33 months after the start.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 33 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634